Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cathepsin S inhibitor
- Development stage
- Preclinical
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal Injection, Intravenous, Nanocarrier-mediated
01
Overview
This cathepsin S inhibitor is a small molecule therapeutic candidate being developed by The First Hospital of Guangxi Medical University for the treatment of liver cancer, specifically hepatocellular carcinoma (HCC). Cathepsin S (CTSS) is a lysosomal cysteine protease that is frequently overexpressed in various malignancies, where it plays a critical role in tumor progression, angiogenesis, and metastasis by degrading extracellular matrix components and modulating the tumor microenvironment. In the context of liver cancer, research from Guangxi Medical University has demonstrated that cathepsin S promotes tumor cell proliferation, invasion, and the epithelial-mesenchymal transition (EMT). Inhibition of this enzyme has been shown to suppress these oncogenic processes and may also influence autophagy and immune evasion mechanisms, such as M2 macrophage polarization, within the liver tumor niche. The program is currently in the early stages of development, focusing on the potential of CTSS inhibition to treat advanced or metastatic liver malignancies.
- Other names
- cathepsin S inhibitor
02
Targets
CTSS (Cathepsin S)
Beyond the preview
Go deeper on cathepsin S inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cathepsin S inhibitor.